RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

Praxis Precision Medicines, Inc. (($PRAX)) has held its Q2 earnings call. Read on for the main highlights of the call. Praxis Precision Medicines, ...

US$6.60 loss per share (further deteriorated from US$4.58 loss in 1H 2024). AI is about to change healthcare. These 20 stocks ...

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) soared 27% on Monday after the company released encouraging top-line ...

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

Praxis Precision Medicines' vormatrigine shows promise in epilepsy with 56.3% seizure reduction. Click here to find out why I ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by ...

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

Pomerantz LLP is investigating claims on behalf of investors of  Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at ...

Praxis Precision Medicines is developing a first-in-class drug in MDD. See why we recommend PRAX stock as a core investment in anticipation of clinical trials.